Bleselumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD40 |
Clinical data | |
Other names | ASKP1240 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6412H9906N1690O2018S38 |
Molar mass | 144175.87 g·mol−1 |
Bleselumab (INN;[1] development code ASKP1240) is a human monoclonal antibody designed for the prevention of organ transplant rejection.[2][3]
This drug was developed by Kyowa Kirin Pharmaceutical Development Inc.[4]
References
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
- ^ Wojciechowski D, Vincenti F (November 2016). "Current status of costimulatory blockade in renal transplantation". Current Opinion in Nephrology and Hypertension. 25 (6): 583–590. doi:10.1097/MNH.0000000000000268. PMID 27517137. S2CID 4379881.
- ^ Malvezzi P, Jouve T, Rostaing L (November 2016). "Costimulation Blockade in Kidney Transplantation: An Update". Transplantation. 100 (11): 2315–2323. doi:10.1097/TP.0000000000001344. PMC 5084636. PMID 27472094.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Bleselumab, American Medical Association.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All stub articles
- Monoclonal antibody stubs
- Monoclonal antibodies